DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20184045

New onset diabetes after transplantation (NODAT) in renal transplant recipients: a study from tertiary care center in Kashmir, India

Mehroz Ahmed, Rahul Sudan, Imtiyaz Ahmed Wani, Muzaffar Maqsood Wani, Khurshid Ahmed Banday, Gunjan Gupta

Abstract


Background: New onset diabetes after transplantation (NODAT) is a common entity in the post-transplant period after several types of organ transplants like kidney, liver heart and lungs. NODAT is a common complication after solid organ transplantation and has been reported to have an adverse impact on patient and allograft outcomes. Risk stratification and intervention to minimize risk should be an integral part of management of transplant recipients.

Methods: A total of 100 patients who underwent renal transplantation were observed for the development of NODAT in the post transplantation period. Patients were evaluated in the pre- transplant and post-transplant period. Risk factors which were associated with the development of NODAT were analyzed.

Results: Out of 100 patients, 79 were males and 21 were females. The mean age of the patients undergoing renal transplantation was 40 years. The youngest patient was 18 years old and the eldest was 64 years old. Majority of the patients were in the age group of 31 to 50 years (60 patients, 60%). The incidence of NODAT in present study was 17%. The major risk factors for the development of NODAT were identified as male sex, positive family history of diabetes, history of alcohol intake before renal transplantation, hypertriglyceridemia, post renal transplantation hypomagnesemia, proteinuria, and use of drugs like tacrolimus and prednisolone.

Conclusions: NODAT has been identified as a risk factor for graft rejection, long-term graft failure, and decreased patient survival. Once NODAT has been diagnosed, specific anti-hyperglycemic therapy is essential to reach a tight glycemic control, which contributes to significantly reduced post-transplantation morbidity. Due to the importance of NODAT, diabetes education and its impact on the outcome of post-transplantation morbidity and mortality becomes crucial point of research among organ transplantation populations. Diabetes education in a group setting can be adopted for organ transplantation recipients with NODAT.


Keywords


Fasting blood glucose, Glycosylated hemoglobin, Impaired glucose tolerance, New onset diabetes after transplantation, Postprandial blood glucose

Full Text:

PDF

References


Davidson JA, Wilkinson A. New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist’s view. Diab Care. 2004 Mar 1;27(3):805-12.

Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, et al. Guidelines for the treatment and management of new‐onset diabetes after transplantation 1. Clinical Tansplantat. 2005 Jun;19(3):291-8.

Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Post transplantation diabetes: a systematic review of the literature. Diab Care. 2002 Mar 1;25(3):583-92.

Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001;59(2):732-37.

Kasiske BL, Snyder JJ, Gilbertson D, Maras AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178-85.

Martı́nez-Castelao A, Hernandez MD, Pascual J, Morales JM, Marcen R, Errasti P, et al. Detection and treatment of post kidney transplant hyperglycemia: a Spanish multicenter cross-sectional study. Transplant Proc. 2005;37(9):3813-6.

Hamer RA, Chow CL, Ong AC, McKane WS. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantat. 2007 Jan 15;83(1):36-40.

Ducloux D, Motte G, Vautrin P, Bresson-Vautrin C, Rebibou JM, Chalopin JM. Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrology, dialysis, transplantation: official publication of the Eur Dialysis Transplant Association-European Renal Assoc. 1999 May 1;14(5):1244-6.

De Mattos AM, Olyaei AJ, Prather JC, Golconda MS, Barry JM, Norman DJ. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int. 2005 Feb 1;67(2):714-20.

Hjelmesaeth J, Hartmann A. Insulin resistance in patients with adult polycystic kidney disease. Nephrol Dial Transplant. 1999;14(10):2521-2.

Jindal RM, Revanur VK, Jardine AG.: Immunosuppression and Diabetogenicity. 1st Ed. Hakim N, Stratta R, Gray D, editors. New York: Oxford University Press. 2002:247-27.

Ekberg H, Tedesco-Silva H, Demirbas A, Vítko Š, Nashan B, Gürkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Eng J Med. 2007 Dec 20;357(25):2562-75.

Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005 Oct 1;16(10):3128-35.

Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19(7):1411-8.

Bonato V, Barni R, Cataldo D, Collini A, Ruggieri G, De Bartolomeis C, et al. Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. Transplant Proc. 2008;40(6):1888-90.

Kissebah AH, Vydelingum N, Murray R, Evans DJ, Kalkhoff RK, Adams PW. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982 Feb 1;54(2):254-60.

Eckel RH. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc Nutrition Soc. 2007;66(1):82-95.

Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant. 2006;6(10):2232-7.

Lehr H, Jao S, Waltzer WC, Anaise D, Rappaport FT. Cytomegalovirus-induced diabetes mellitus in a renal transplant recipient. Transplant Proc. 1985;17(5):2152-4.

Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007 Jun;7(6):1506-14.

Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kakinuma H, et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantat. 2005 Nov 27;80(10):1419-24.

Sulanc E, Lane JT, Puumala SE, Groggel GC, Wrenshall LE, Stevens RB. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplant. 2005 Oct 15;80(7):945-52.

Lutsey PL, Pankow JS, Bertoni AG, Szklo M, Folsom AR. Serological evidence of infections and type 2 diabetes: the multi ethnic Study of Atherosclerosis. Diabet Med. 2009;26:149-52.

Chakkera HA, Hanson RL, Raza SM, DiStefano JK, Millis MP, Heilman RL, et al. Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation. Transplant Proc. 2009;41:4172-77.

Van Laecke ST, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. Post transplantation hypomagnesemia and its relation with immunosuppression as predictors of new‐onset diabetes after transplantation. Am J Transplant. 2009;9(9):2140-9.

Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nature Genet. 2010 Jul;42(7):579.

Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Investigat. 2007 Aug 1;117(8):2155-63.

Ghisdal L, Baron C, Le Meur Y, Lionet A, Halimi JM, Rerolle JP, et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol. 2009 Nov 1;20(11):2459-67.

Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: an underdiagnosed phenomenon. Transplant. 2006 Dec 27;82(12):1667-72.